Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022


ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m. ET to report financial results for the third quarter 2022 and provide business updates.

To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics' CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.


These press releases may also interest you

at 22:05
Trulioo 24/7 Support Empowers Top APAC Region Companies to Expand Into New Markets, Achieve Compliance and Accelerate Customer Onboarding
Trulioo, an industry-leading identity platform with proven global coverage for person and business verification, today marked the one-year anniversary of its Singapore office by highlighting how its 24/7 implementation support helps Asia-Pacific...

at 22:00
Zetrix/MYEG and MaiCapital Ink MoU to Launch Virtual Asset Funds
Zetrix Foundation and MY E.G. Services Berhad ("MYEG") signed a Memorandum of Understanding (MoU) with MaiCapital, a licensed virtual asset manager in Hong Kong, to collaborate on the launch of a virtual asset fund or Hong Kong virtual assets...

at 21:15
Jesper and Jesse Will Work Together Again at rabbit!
Today, Santa Monica-based AI startup rabbit inc. has announced the appointment of Jesper Kouthoofd, founder of teenage engineering, as Chief Design Officer at rabbit. Together with rabbit founder and CEO Jesse Lyu, Kouthoofd will guide the future...

at 20:38
An adventure every day after school: Boys and Girls Clubs of Central Arizona
The Boys and Girls Clubs of Central Arizona proudly announce their ongoing commitment to youth development in the Prescott and Prescott Valley communities. As a cornerstone of local enrichment and learning, the Clubs provide a nurturing environment...

at 20:30
Nium and Thredd Expand Partnership to Power B2B Travel Payments in APAC
Nium, the global leader in real-time cross-border payments, today announced the expansion of its partnership with Thredd, a leading global payments processor, to issue virtual cards in the Asia Pacific (APAC) region.     Nium's virtual card solution...

at 19:13
LG Energy Solution to Take Firm Stance Against Patent Infringers
A surge in patent infringement by latecomers in the battery industry, and subsequent market distortion caused by unlicensed use of patented technology, calls for strong countermeasures to level the playing fieldLG Energy Solution believes that at...

More news about Science and technology...


News published on and distributed by: